Attovia Therapeutics priced an upsized IPO raising $289 million to fund clinical development of its immune disorder pipeline and broaden R&D in 2027. The listing extends a stretch of biotech debuts in the sector’s recent IPO wave, highlighting sustained investor appetite for late-stage-ready biology. Separate reporting placed Attovia among the biggest July 2026 biotech financings, emphasizing how quickly the company moved through market windows after strengthening investor demand for new immunology and inflammation candidates.